← Back to patent-cliff list
Bemnifosbuvir/Ruzasvir
Tier C — Watch / tradeBemnifosbuvir/Ruzasvir
Atea Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NS5B, RdRp, NS5A
Indications (approved)：Hepatitis C, Chronic hepatitis C, Hepatic function decline, Renal impairment
Regional status
US
Phase III
2025-04-07
EU
Phase III
2025-06-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bemnifosbuvir/Ruzasvir?
Approved indications include: Hepatitis C, Chronic hepatitis C, Hepatic function decline, Renal impairment.
When does the Bemnifosbuvir/Ruzasvir patent expire?
No public expiry year is available for Bemnifosbuvir/Ruzasvir yet; this page updates once verified.
How do I get a quote for Bemnifosbuvir/Ruzasvir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30